NOVA.DE
Novo Nordisk A/S News
Sign up for free!
Get instant access to all of our market news and analysis with our free REST API.
Latest news
Live response for past 24 hours
{
"meta": {
"found": 7,
"returned": 7,
"limit": 10,
"page": 1
},
"data": [
{
"uuid": "541d52d8-0b5b-4fba-a8cd-799fe6fa18c4",
"title": "NOVO NORDISK : JP Morgan gives a Buy rating",
"description": "Richard Vosser from JP Morgan retains his positive opinion on the stock with a Buy rating. The target price remains set at DKK 950.",
"keywords": "Markets",
"snippet": "Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabe...",
"url": "https://www.marketscreener.com/quote/stock/NOVO-NORDISK-A-S-1412980/news/NOVO-NORDISK-JP-Morgan-gives-a-Buy-rating-46619178/",
"image_url": "https://www.marketscreener.com/images/twitter_MS_fdblanc.png",
"language": "en",
"published_at": "2024-05-03T06:32:35.000000Z",
"source": "marketscreener.com",
"relevance_score": null,
"entities": [
{
"symbol": "NOVA.DE",
"name": "Novo Nordisk A/S",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 50.09293,
"sentiment_score": 0,
"highlights": [
{
"highlight": "<em>Novo</em> <em>Nordisk</em> <em>A</em>/<em>S</em> specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (92.6%); - rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "3b0c1c2e-4f83-419f-9f09-7396f6c26002",
"title": "Q1 2024 Novo Nordisk A/S Earnings Call Transcript",
"description": "May 02, 2024 / 11:00AM GMTOperator Good day, and thank you for standing by. Welcome to the Q1 2024 Novo Nordisk AS Earnings Conference Call. (Operator Instructi",
"keywords": "GuruFocus, Article, News, GuruFocus Research, NYSE:NVO",
"snippet": "May 02, 2024 / 11:00AM GMT\n\nOperator\n\n\n\nGood day, and thank you for standing by. Welcome to the Q1 2024 Novo Nordisk AS Earnings Conference Call. (Operator Inst...",
"url": "https://www.gurufocus.com/news/2426340/q1-2024-novo-nordisk-as-earnings-call-transcript",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2024-05-03T05:12:46.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "NOVA.DE",
"name": "Novo Nordisk A/S",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 165.50948,
"sentiment_score": 0.33525,
"highlights": [
{
"highlight": "Daniel Bohsen - <em>Novo</em> <em>Nordisk</em> <em>A</em>/<em>S</em>-CVP&Head of IR\n\n\n\nThank you. Welcome to this Novo Nordisk Earnings call for the first 3 months of 2024. My name is Daniel Muusmann Bohsen, and I'm the Head of Investor Relations at Novo Nordisk.",
"sentiment": 0.6705,
"highlighted_in": "main_text"
},
{
"highlight": "Q1 2024 <em>Novo</em> <em>Nordisk</em> <em>A</em>/<em>S</em> Earnings Call Transcript",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "58c2836b-005c-4b69-a950-7f050fe064e3",
"title": "Amgen Soars After CEO Gives Update on Experimental Obesity Drug",
"description": "Amgen Inc.’s shares soared in late trading after its chief executive officer said he was “very encouraged” by early results from a study of the company’s experimental obesity drug, MariTide.",
"keywords": "Amgen Inc., shares, obesity drug, MariTide, weight-loss",
"snippet": "Amgen Inc.’s shares soared in late trading after its chief executive officer said he was “very encouraged\" by early results from a study of the company’s ...",
"url": "https://www.livemint.com/news/amgen-soars-after-ceo-gives-update-on-experimental-obesity-drug-11714686711922.html",
"image_url": "https://images.livemint.com/img/2018/12/28/1600x900/News_-_world_1545994908237.jpg",
"language": "en",
"published_at": "2024-05-02T21:51:51.000000Z",
"source": "livemint.com",
"relevance_score": null,
"entities": [
{
"symbol": "NOVA.DE",
"name": "Novo Nordisk A/S",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 38.00384,
"sentiment_score": 0.2023,
"highlights": [
{
"highlight": "The Thousand Oaks, California-based company has emerged as a potential competitor to Eli Lilly & Co. and <em>Novo</em> <em>Nordisk</em> <em>A</em>/<em>S</em>, whose dominance of the weight-loss market so far remains unchallenged.",
"sentiment": 0.2023,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "5969c065-05a0-4d0c-9e0c-5f3afa325427",
"title": "Ascendis Pharma A/S : Form 6-K",
"description": "6-K\n \n \n \n \n \n UNITED STATES \n \n \n SECURITIES AND EXCHANGE COMMISSION \n \n \n Washington, D.C. 20549 \n \n \n \n FORM 6-K \n \n \n \n ...",
"keywords": "Markets",
"snippet": "6-K\n\nUNITED STATES\n\nSECURITIES AND EXCHANGE COMMISSION\n\nWashington, D.C. 20549\n\nFORM 6-K\n\nREPORT OF FOREIGN PRIVATE ISSUER\n\nPURSUANT TO SECTION 13a-16 OR 15d-16...",
"url": "https://www.marketscreener.com/quote/stock/ASCENDIS-PHARMA-A-S-20566532/news/Ascendis-Pharma-A-S-Form-6-K-46610830/",
"image_url": "https://www.marketscreener.com/images/twitter_MS_fdblanc.png",
"language": "en",
"published_at": "2024-05-02T20:59:14.000000Z",
"source": "marketscreener.com",
"relevance_score": null,
"entities": [
{
"symbol": "NOVA.DE",
"name": "Novo Nordisk A/S",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 3.400902,
"sentiment_score": 0.4215,
"highlights": [
{
"highlight": "All currently marketed daily hGH products in the United States - Norditropin®(<em>Novo</em> <em>Nordisk</em> <em>A</em>/<em>S</em>), Humatrope®(Eli Lilly and Company), Genotropin®(Pfizer Inc.), Zomacton®(Ferring Pharmaceuticals, Inc.) and Omnitrope®(Sandoz GmbH) - contain unmodified somatropin (hGH) and are administered by subcutaneous injections.",
"sentiment": 0.4215,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "d4e49f66-6d32-4c16-89f0-a04993e8338c",
"title": "Novo Nordisk A/S 2024 Q1 - Results - Earnings Call Presentation (NYSE:NVO)",
"description": "The following slide deck was published by Novo Nordisk A/S in conjunction with their 2024 Q1 earnings call.",
"keywords": "",
"snippet": "To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.\n\nIf you have an ad-blocker enabled you may be blocked from ...",
"url": "https://seekingalpha.com/article/4688575-novo-nordisk-s-2024-q1-results-earnings-call-presentation",
"image_url": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
"language": "en",
"published_at": "2024-05-02T16:25:25.000000Z",
"source": "seekingalpha.com",
"relevance_score": null,
"entities": [
{
"symbol": "NOVA.DE",
"name": "Novo Nordisk A/S",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 154.0611,
"sentiment_score": 0,
"highlights": [
{
"highlight": "<em>Novo</em> <em>Nordisk</em> <em>A</em>/<em>S</em> 2024 Q1 - Results - Earnings Call Presentation (NYSE:NVO)",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "aab50636-ff68-432f-bb6a-b900af7eb180",
"title": "Novo Nordisk A/S (NVO) Q1 2024 Earnings Call Transcript",
"description": "Novo Nordisk A/S (NVO) Q1 2024 Earnings Conference Call May 2, 2024 7:00 AM ETCompany ParticipantsLars Fruergaard Jørgensen - Chief Executive Officer...",
"keywords": "",
"snippet": "Novo Nordisk A/S (NVO) Q1 2024 Earnings Conference Call May 2, 2024 7:00 AM ET\n\nCompany Participants\n\nLars Fruergaard Jørgensen - Chief Executive Officer\n\nCami...",
"url": "https://seekingalpha.com/article/4688571-novo-nordisk-s-nvo-q1-2024-earnings-call-transcript",
"image_url": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
"language": "en",
"published_at": "2024-05-02T16:21:14.000000Z",
"source": "seekingalpha.com",
"relevance_score": null,
"entities": [
{
"symbol": "NOVA.DE",
"name": "Novo Nordisk A/S",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 159.5661,
"sentiment_score": 0.2162,
"highlights": [
{
"highlight": "<em>Novo</em> <em>Nordisk</em> <em>A</em>/<em>S</em> (NVO) Q1 2024 Earnings Conference Call May 2, 2024 7:00 AM ET\n\nCompany Participants\n\nLars Fruergaard Jørgensen - Chief Executive Officer\n\nCamilla Sylvest - Executive Vice President, Head of Commercial Strategy & Corporate Affairs\n\nDoug Langa - Executive Vice President, Head of North America Operations\n\nMartin Holst Lange - Executive",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Welcome to the Q1, 2024 <em>Novo</em> <em>Nordisk</em> <em>A</em>/<em>S</em> Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. [Operator Instructions]. Please be advised that today's conference is being recorded.",
"sentiment": 0.6486,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Novo</em> <em>Nordisk</em> <em>A</em>/<em>S</em> (NVO) Q1 2024 Earnings Call Transcript",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "0d89238a-9792-4d3e-ba23-44cf642ebb0b",
"title": "'Nearly priced for perfection': Unforgiving investors want bumper earnings after record rally",
"description": "It’s taking bumper earnings and profit forecasts to impress investors, after a record rally this year left stocks looking expensive. Read on",
"keywords": "",
"snippet": "This advertisement has not loaded yet, but your article continues below.\n\n'Nearly priced for perfection': Unforgiving investors want bumper earnings after recor...",
"url": "https://financialpost.com/investing/investors-want-bumper-earnings-after-record-rally",
"image_url": "https://smartcdn.gprod.postmedia.digital/financialpost/wp-content/uploads/2024/05/earnings-guidance-gs0502.png",
"language": "en",
"published_at": "2024-05-02T14:44:41.000000Z",
"source": "thepost.on.ca",
"relevance_score": null,
"entities": [
{
"symbol": "NOVA.DE",
"name": "Novo Nordisk A/S",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Healthcare",
"match_score": 22.086338,
"sentiment_score": 0.8074,
"highlights": [
{
"highlight": "<em>Novo</em> <em>Nordisk</em> <em>A</em>/<em>S</em>, which makes the weight-loss drug Wegovy, slipped even as it raised its profit outlook. The main reason, many reckon, is the S&P 500’s 28 per cent rally from its October lows through the end of March, which raised expectations of strong profits.",
"sentiment": 0.8074,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
}
]
}
Sentiment
Live response for past 24 hours
{
"meta": {
"returned": 1,
"limit": 10
},
"data": [
{
"key": "NOVA.DE",
"total_documents": 7,
"sentiment_avg": 0.2832357095820563
}
]
}
Other details
Exchange
- Deutsche Börse Xetra
- equity
- Healthcare
- de